Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Ganli Pharmaceutical: Clinical trial application for the new indication of Bofanglu peptide injection approved
Gan Li Pharmaceutical announced that its wholly-owned subsidiary, Gan Li Pharmaceutical Shandong Co., Ltd., has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration regarding the investigational drug Bofanglurutide (development code: GZR18) injection for the new indication of “Moderate to severe obstructive sleep apnea in adult obese patients.” The acceptance numbers are CXSL2600050, CXSL2600051, CXSL2600052, CXSL2600053, CXSL2600054, CXSL2600055, CXSL2600056, CXSL2600057, and the notice numbers are 2026LP00892, 2026LP00893, 2026LP00894, 2026LP00895, 2026LP00896, 2026LP00897, 2026LP00898, 2026LP00899. Bofanglurutide (development code: GZR18) injection is a glucagon-like peptide-1 receptor agonist (GLP-1RA) developed independently by Gan Li Pharmaceutical, administered once every two weeks.